SCHEMBL3014758

SCHEMBL3014758

COc1cc(-c2csc(N3CCN(S(=O)(=O)c4cccc([N+](=O)[O-])c4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
USP2 O75604 2/20 0.55
RECQL P46063 1/20 0.55
HSD17B10 Q99714 1/20 0.55
ALDH1A1 P00352 5/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 3/20 0.48
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
HPGD P15428 1/20 0.48
GBA1 P04062 2/20 0.47
POLB P06746 1/20 0.47
KMO O15229 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018048 0.91 MAPT (0.57) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3005877 0.91 MAPT (0.56) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3020254 0.90 MAPT (0.64) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3013618 0.88 MAPT (0.61) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3015882 0.87 MAPT (0.54) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3016277 0.87 MAPT (0.73) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3017989 0.87 SMN1; SMN2 (0.53) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3013276 0.86 ALDH1A1 (0.50) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3016857 0.86 ALDH1A1 (0.52) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3011827 0.86 MAPT (0.56) MAPTUSP2RECQLHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.